This is the first analysis of the cost-effectiveness of liraglutide 1.8 mg compared with lixisenatide 20 μg, each added to basal insulin, in patients with T2D uncontrolled on basal insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.